Nervous Disorder TRIZ Cases

Recombinant AAV9 delivers MECP2 to neurons and astrocytes via intrathecal injection.

Furosemide analogues inhibit amyloid-beta aggregation and reduce neuroinflammation to treat Alzheimer's disease.

Lactobacillus plantarum PDA6 modulates BDNF, 5-HT, and GABA expression levels through gut-brain axis signaling pathways.

Transfecting neural stem cells with NICD or treating them with HGF activates signaling pathways to overcome limited proliferative capacity.

PI3K inhibitor blocks differentiation to increase T cell numbers and persistence.

Sucrose fatty acid mono-ester granulates protect cannabidiol from first-pass liver metabolization, achieving high and predictable bioavailability.

A CCL1-Ig fusion polypeptide induces regulatory T cells to suppress effector T cell activity.

RNA interference targets SCN9A mRNA to reduce Nav1.7 channel expression in peripheral neurons.

Target skull suture lines with botulinum toxin to improve injection precision and reduce dosage while alleviating headache pain.

A nutritional supplement combining uridine, choline, DHA, and EPA to improve language development scores in children with cerebral palsy.

RXR agonist therapy promotes remyelination while avoiding hypothyroidism through precise dose adjustments that maintain stable T4 levels.

Squid-derived peptides activate the V1B receptor, addressing limited research progress and enabling targeted treatment of stress-related diseases.

Frictional fixing projections hold the storage means in place while a liner prevents oil diffusion into the sleeve material.

Transglutaminase attaches an albumin binding residue to growth hormone, extending half-life and reducing administration frequency.

A transdermal patch delivers capsaicin, lidocaine, and alpha-lipoic acid to manage neuropathic pain.

Palmitoylethanolamide and fatty acid mixture regulates cell receptor activity to control inflammatory processes without corticosteroid side effects.

Lipopolysaccharide-binding protein targets amyloid formation and systemic inflammation to slow Alzheimer's disease progression.

Direct transcription factor expression resolves low efficiency and purity trade-offs in stem cell differentiation.

C5 ketone compositions increase blood ketone levels to enhance cognitive function and physical performance.

ALDH-promoting agents reduce endometrial tissue size and alleviate pain, addressing the trade-off between long-term relief and side effects.

Pegylated IL-10 administration uses dynamic dosing parameters to resolve the contradiction between improved tumor control and increased adverse effects.

Administering fibrates or retinoic acid to upregulate Transcription Factor EB and increase lysosomal biogenesis.

Negative allosteric modulators target alpha5 subunit-containing GABAA receptors to produce rapid antidepressant action.

A palladium catalyzed coupling process prepares opioid receptor modulators from alternative starting materials.

Universal screening tests quantify organ-enriched miRNAs in bodily fluids to detect pathological changes early.

Mangosteen pericarp extracts reduce schizophrenia symptom severity and antipsychotic side effects by neutralizing oxidative stress.

Recombinant adeno-associated virus delivers CLN2 coding sequences to central nervous system cells.

Quinoxaline compounds inhibit IKKβ and NFκB pathways, resolving measurement complexity in phosphorylation detection.

Novel heterocyclic compounds featuring a di(pyridin-2-yl)methylene moiety modulate bromodomains with superior pharmacokinetic properties.

Pseudouridine-modified RNA prevents innate immune receptor activation and double-stranded RNA formation while inducing antigen-specific tolerance.

Selective PKC activators resolve the contradiction between reducing amyloid-beta levels and preventing synaptic loss by targeting specific enzyme isoforms.

Secondary amine-based mutual prodrugs merge NFkB and CDK inhibitors to eliminate inactive fragment release, resolving stability and adverse effect trade-offs.

1-(2-fluorobiphenyl-4-yl)-alkyl carboxylic acid derivatives bind transthyretin to stabilize its tetrameric state.

Combination therapy uses anti-Tau and PEG-anti-Aβ antibodies to reduce plaque levels while lowering side effects from single-agent dosing.

Integrates Nurr1 agonists with aldosterone antagonists and sulfonylureas to reduce infarct size while minimizing adverse drug interactions.

Boronated compounds scavenge reactive oxygen species and chelate metal ions, reducing toxicity while improving solubility and bioavailability.

A veterinary supplement combines alpha-lactalbumin and magnesium to promote serotonin production in pets.

Modifying the amino acid sequence of a pine nut-derived peptide enhances antioxidant capacity and stability while resolving synthesis complexity constraints.

A rotating roller applies etchant to wafer edges for simultaneous multi-wafer processing.

Formula I compounds inhibit METTL3 activity to resolve contradictions between reducing cancer cell proliferation and preserving protective immune responses.

Administering isolated CD44V10 peptides protects neurons from neurotoxic agents, addressing the progressive loss of neurons in neurodegenerative disorders.

Single-source eggplant extraction simplifies preparation complexity and lowers manufacturing costs while maintaining psychological state improvement.

ABPPk2 peptide reduces neuronal damage by inhibiting glutamate receptors, resolving insufficient neuroprotection in ischemic stroke.

Floating gastroretentive dosage form prevents premature transit through the pyloric sphincter, ensuring reliable gastric retention and therapeutic efficacy.

A peptide sequence inhibits alpha-synuclein oligomer binding to v-SNARE proteins.

Antibodies recognize unique oligomeric structures to neutralize neurotoxic species without triggering inflammatory responses or binding monomers.